Original Research

Published on 06 Dec 2022

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

in Pharmacology of Anti-Cancer Drugs

Elena Karg
Christoph Baldow
Thomas Zerjatke
Richard E. Clark
Ingo Roeder
Artur C. Fassoni
Ingmar Glauche

Frontiers in Oncology

doi 10.3389/fonc.2022.1028871

1,779 views
5 citations

Brief Research Report

Published on 01 Dec 2022

Microenvironmental changes co-occur with mosaic somatic clonal expansions in normal skin and esophagus tissues

in Pharmacology of Anti-Cancer Drugs

C. Munugula
J. Hu
E. Christodoulou
V. Yellapantula

Frontiers in Oncology

doi 10.3389/fonc.2022.1021940

1,177 views
1 citation

Mini Review

Published on 29 Nov 2022

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

in Pharmacology of Anti-Cancer Drugs

Sahar F. Bannoura
Husain Yar Khan
Asfar S. Azmi

Frontiers in Oncology

doi 10.3389/fonc.2022.1013902

25,928 views
43 citations

Mini Review

Published on 24 Nov 2022

Targeting autophagy in pancreatic cancer: The cancer stem cell perspective

in Pharmacology of Anti-Cancer Drugs

Dimitrios Troumpoukis
Adriana Papadimitropoulou
Chrysanthi Charalampous
Paraskevi Kogionou
Kostas Palamaris
Panagiotis Sarantis
Ioannis Serafimidis

Frontiers in Oncology

doi 10.3389/fonc.2022.1049436

3,669 views
5 citations

Original Research

Published on 23 Nov 2022

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

in Pharmacology of Anti-Cancer Drugs

Maria Antonietta Barbieri
Emanuela Elisa Sorbara
Giuseppe Cicala
Vincenza Santoro
Paola Maria Cutroneo
Tindara Franchina
Mariacarmela Santarpia
Nicola Silvestris
Edoardo Spina

Frontiers in Oncology

doi 10.3389/fonc.2022.1005626

3,408 views
17 citations

Original Research

Published on 15 Nov 2022

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

in Pharmacology of Anti-Cancer Drugs

Rossella Iula
Danilo De Novellis
Fabio Trastulli
Roberta Della Pepa
Raffaele Fontana
Angela Carobene
Maria Di Perna
Alessandro D’Ambrosio
Martina Romano
Aldo Leone

Frontiers in Oncology

doi 10.3389/fonc.2022.1026251

2,554 views
14 citations

Review

Published on 15 Nov 2022

Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment

in Pharmacology of Anti-Cancer Drugs

Jiaxin Zhang
Huiqiong Han
Lei Wang
Wenjia Wang
Mei Yang
Yanru Qin

Frontiers in Oncology

doi 10.3389/fonc.2022.988956

4,073 views
5 citations

Review

Published on 15 Nov 2022

A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution

in Pharmacology of Anti-Cancer Drugs

Peng Song
Hui Li
Kuo Xu
Zi-Wei Li
Xia Ren
Xian-Jun Fu

Frontiers in Oncology

doi 10.3389/fonc.2022.905868

2,506 views
2 citations

Brief Research Report

Published on 10 Nov 2022

Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic

in Pharmacology of Anti-Cancer Drugs

Jana Stojanova
Jane E. Carland
Bridin Murnion
Vincent Seah
Jim Siderov
Florian Lemaitre

Frontiers in Oncology

doi 10.3389/fonc.2022.959741

4,401 views
3 citations

Original Research

Published on 10 Nov 2022

Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression

in Pharmacology of Anti-Cancer Drugs

Wei Huang
Shu Yang
Yu-Shan Cheng
Ni Sima
Wei Sun
Min Shen
John C. Braisted
Weiguo Lu
Wei Zheng

Frontiers in Oncology

doi 10.3389/fonc.2022.1068443

2,437 views
5 citations

Original Research

Published on 03 Nov 2022

Mediating effect assessment of ifosfamide on limb salvage rate in osteosarcoma: A study from a single center in China

in Pharmacology of Anti-Cancer Drugs

Yan Li
Yiwei Fu
Zhaohui Zhang
Zhuo Wang
Junqiang Yin
Jingnan Shen

Frontiers in Oncology

doi 10.3389/fonc.2022.1046199

1,808 views
1 citation

Systematic Review

Published on 03 Nov 2022

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma

in Pharmacology of Anti-Cancer Drugs

Angiolo Gadducci
Stefania Cosio

Frontiers in Oncology

doi 10.3389/fonc.2022.914342

5,996 views
14 citations

Original Research

Published on 02 Nov 2022

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models

in Pharmacology of Anti-Cancer Drugs

Andrea Mancini
Alessandro Colapietro
Loredana Cristiano
Alessandra Rossetti
Vincenzo Mattei
Giovanni Luca Gravina
Héctor Perez-Montoyo
Marc Yeste-Velasco
Jose Alfon
Carles Domenech

Frontiers in Oncology

doi 10.3389/fonc.2022.943064

2,496 views
6 citations

Original Research

Published on 01 Nov 2022

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis

in Pharmacology of Anti-Cancer Drugs

Taojun Gong
Qi Huang
Fan Tang
Yitian Wang
Zhuangzhuang Li
Yi Luo
Li Min
Yong Zhou
Chongqi Tu

Frontiers in Oncology

doi 10.3389/fonc.2022.1031787

1,386 views
1 citation

Editorial

Published on 01 Nov 2022

Editorial: The effects of chemotherapy towards the tumor microenvironment

in Pharmacology of Anti-Cancer Drugs

Nadiah Abu
Alice Turdo
Jose A. Garcia-Sanz

Frontiers in Oncology

doi 10.3389/fonc.2022.1069561

1,440 views
2 citations

Review

Published on 31 Oct 2022

Immunometabolism in the tumor microenvironment and its related research progress

in Pharmacology of Anti-Cancer Drugs

Ziheng Zhang
Yajun Hu
Yuefeng Chen
Zhuoneng Chen
Yexin Zhu
Mingmin Chen
Jichu Xia
Yixuan Sun
Wenfang Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.1024789

4,359 views
15 citations

Navigation group

Articles

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

Microenvironmental changes co-occur with mosaic somatic clonal expansions in normal skin and esophagus tissues

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Targeting autophagy in pancreatic cancer: The cancer stem cell perspective

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment

A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution

Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic

Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression

Mediating effect assessment of ifosfamide on limb salvage rate in osteosarcoma: A study from a single center in China

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis

Editorial: The effects of chemotherapy towards the tumor microenvironment

Immunometabolism in the tumor microenvironment and its related research progress